@article{Stuart_A-2021_50774, title = {Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial}, author = {Stuart, A. and Shaw, R. and Liu, X. and Greenland, M. and Aley, P. and Andrews, N. and Cameron, C. and Charlton, S. and Clutterbuck, E. and Collins, A. and Darton, T. and Dinesh, T. and Duncan, C. and England, A. and Faust, S. and Ferreira, D. and Finn, A. and Goodman, A. and Green, C. and Hallis, B. and Heath, P. and Hill, H. and Horsington, B. and Lambe, T. and Lazarus, R. and Libri, V. and Lillie, P. and Mujadidi, Y. and Payne, R. and Plested, E. and Provstgaard-Morys, S. and Ramasamy, M. and Ramsay, M. and Read, R. and Robinson, H. and Screaton, G. and Singh, N. and Turner, D. and Turner, P. and Vichos, J. and White, R. and Nguyen-Van-Tam, J. and Snape, M. and Com-COV2 Study Group}, month = {dec}, year = {2021}, abstract = {BackgroundGiven the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer–BioNTech, and mRNA-1273 [m1273], Moderna) and ananoparticlevaccine containing SARS-CoV-2 spikeglycoproteinand Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).}, journal = {The Lancet}, publisher = {Elsevier}, url = {https://doi.org/10.1016/S0140-6736(21)02718-5}, }